Combination bevacizumab plus temsirolimus for second-line treatment of metastatic kidney cancer
A recent phase 2 study evaluated the combination of bevacizumab [...]
Safety and tolerability of atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer
The combined safety results of two studies with the atezolizumab [...]
Potential biomarkers may predict response to TKIs in metastatic kidney cancer
A recent study published in Clinical Cancer Research and conducted in [...]
Patient-reported outcomes for atezolizumab plus bevacizumab combination
Patient-reported outcomes from the phase 3 IMmotion151 study, which assessed [...]
Combination therapies for kidney cancer
The following is a Practice Update interview with Dr Hans Hammers, Associate [...]
Atezolizumab plus bevacizumab combination is positive for untreated metastatic kidney cancer
The combination of immunotherapy atezolizumab (Tecentriq) with targeted therapy bevacizumab [...]
Positive interim results for atezolizumab plus bevacizumab combination in advanced RCC
Interim results from the phase III IMmotion151 study to assess [...]
Results from the IMmotion 150 clinical trial comparing atezolizumab with sunitinib
In this interview, Dr Daniel George from the Duke Cancer Institute, Durham, [...]
Combination treatment with atezolizumab plus bevacizumab improves progression-free survival
Results from the IMmotion150 phase II clinical trial showed that [...]
Type of long-term response to targeted therapy affects outcomes for advanced kidney cancer
A retrospective study conducted by researchers in the Czech Republic [...]
